Novo Nordisk A/S Form 6-K Summary
Business Context and Reporting Period
This Form 6-K reports the unaudited consolidated financial results for Novo Nordisk A/S for the full year ended 31 December 2025, filed on 4 February 2026. The company is a global healthcare leader focused on diabetes, obesity, and rare diseases. The reporting period concludes the 2025 Strategic Aspirations, which saw sales and operating profit more than double since 2019.
Key Financial Metrics (2025)
| Metric | 2025 (DKK million) | 2024 (DKK million) | Growth (Reported) | Growth (CER*) |
|---|---|---|---|---|
| Net Sales | 309,064 | 290,403 | 6% | 10% |
| Operating Profit | 127,658 | 128,339 | (1%) | 6% |
| Net Profit | 102,434 | 100,988 | 1% | N/A |
| Diluted EPS | 23.03 | 22.63 | 2% | N/A |
| Free Cash Flow | 28,295 | (14,707) | N/A | N/A |
| Capital Expenditure (PP&E) | 60,140 | 47,164 | 28% | N/A |
| Net Debt | (95,424) | (69,713) | N/A | N/A |
*CER: Constant Exchange Rates (average 2024 rates).
Segment Performance: Obesity care sales grew 31% at CER to DKK 82.3 billion, driven by Wegovy. Diabetes care sales grew 4% at CER to DKK 207.1 billion. Rare disease sales grew 9% at CER to DKK 19.6 billion.
Material Changes vs. Prior Period
- Restructuring Impact: Operating profit decreased 1% as reported due to approximately DKK 8 billion in one-off restructuring costs related to a company-wide transformation. Excluding these costs, operating profit would have increased 13% at CER.
- Gross Margin Compression: Gross margin declined to 81.0% from 84.7% in 2024, impacted by amortization of acquired Catalent sites, restructuring costs, and negative currency effects.
- Free Cash Flow Recovery: Free cash flow turned positive to DKK 28.3 billion, a significant improvement from a negative DKK 14.7 billion in 2024, primarily due to the absence of the DKK 11.7 billion Catalent acquisition payment made in 2024.
- Employee Count: Full-time equivalent employees decreased by 10% to 68,794, reflecting the company-wide transformation.
Guidance, Outlook, and Risks
2026 Guidance (Adjusted):
- Adjusted Sales Growth: Expected to be -5% to -13% at CER. Reported growth in DKK is expected to be ~3 percentage points lower.
- Adjusted Operating Profit Growth: Expected to be -5% to -13% at CER. Reported growth in DKK is expected to be ~5 percentage points lower.
Key Drivers and Risks:
- 340B Reversal: Sales and operating profit in 2026 will be positively impacted by a reversal of USD 4.2 billion in sales rebate provisions related to the US 340B Drug Pricing Program. This amount is excluded from the "Adjusted" guidance metrics.
- Pricing Headwinds: Outlook reflects lower realized prices due to the US "Most Favoured Nations" agreement and patent expiries for semaglutide in certain international markets.
- Competition: Intensifying competition in the GLP-1 market is expected to impact market share and pricing.
- Legal Matters: Ongoing litigation regarding the 340B program and antitrust claims in China and the US. A favorable ruling in the US regarding 340B policy led to the planned revenue reversal.
Capital Allocation:
- Dividends: Proposed final dividend of DKK 7.95 per share, totaling DKK 11.70 for 2025.
- Share Repurchase: New program approved for up to DKK 15 billion to be executed over the next 12 months.
Investor Verification Checklist
- 340B Revenue Recognition: Verify the timing and accounting treatment of the USD 4.2 billion revenue reversal expected in Q1 2026.
- Adjusted Metrics Definition: Review Appendix 7 for the specific definitions of "Adjusted Sales" and "Adjusted Operating Profit" to ensure comparability with peer companies.
- Wegovy Pill Uptake: Monitor prescription volumes for the newly launched oral semaglutide (Wegovy pill) to assess its contribution to offsetting pricing headwinds.
- Restructuring Savings: Track the realization of cost savings from the company-wide transformation to validate the long-term margin outlook.
- Legal Outcomes: Monitor the status of the pending Seventh Circuit appeal regarding the 340B program and the antitrust lawsuit in China.